Rapid Dose Therapeutics (RDT) specializes in innovative drug delivery technologies, primarily through its proprietary QuickStrip™ system. This oral fast-dissolving drug delivery method allows for the rapid release of a wide range of pharmaceuticals, including micronized oils and over-the-counter medications. QuickStrip™ is designed to bypass first-pass metabolism in the liver, enabling active pharmaceutical ingredients (APIs) to enter the bloodstream quickly and efficiently. Studies indicate that the pharmacokinetics of QuickStrip™ delivery closely resemble those of intravenous injections, providing a fast and effective alternative for medication administration.

In addition to QuickStrip™, RDT employs the RDMx technology, which enhances the delivery of poorly soluble pharmaceuticals by utilizing a film-forming agent to create a homogenous composition. This technology is particularly beneficial for large therapeutic molecules, such as proteins, and can be adapted for various proprietary formulations across multiple therapeutic classes. The QuickStrip™ product can be easily administered by placing it under the tongue or inside the cheek, where it dissolves rapidly, facilitating swift absorption into the bloodstream. Overall, RDT's technologies aim to improve patient outcomes and enhance the quality of life through efficient drug delivery solutions.

Canada

We are a Canadian publicly traded Canadian life-sciences company that provides innovation, proprietary drug delivery technologies designed to improve outcomes and quality of lives. RDT offers quick, convenient precise and discreet™ and smoke-free choices to consumers. RDT is focused on clinical research and product development for the healthcare manufacturing industry, including nutraceutical, pharmaceutical and cannabis industries. RDT is committed to innovative solutions for future market needs — including humans, animals and plants.

We are now publicly listed on the Canadian Securities Exchange: $DOSE. 

Rapid Dose Therapeutics

Company Details